LabCorp, now the owner of CRO giant Covance, partnered up with Japan's Sysmex to bring in some new technology it believes will make its subsidiary more competitive in the market for oncology clinical trials.
WuXi PharmaTech's NextCODE secured a spot among the companies and research institutions taking part in Genomics England, contending for a lead role in the group's ambitious effort to sequence the genomes of 100,000 people.
Quintiles has opened up a new, up-sized headquarters in China, toasting the country's growth as a global biopharma power and angling to play a bigger role in its continued evolution.
Contract drug developer Recipharm has inked a deal with Swedish biotech Follicum to help get the company's top prospect into clinical trials, handling formulation and production.
Contract drugmaker AMRI is shifting some of its focus to early-stage R&D, partnering up with a neighboring biotech to expand its capabilities in drug discovery.
CRO giant Parexel has updated its technology for patient randomization and clinical supply management, touting the latest version as a valuable tool for speeding up the process of designing studies.
DaVita Clinical Research, which handles outsourced trials for the kidney care giant, is expanding its European presence, bringing in global experts to extend its network of R&D sites.
BioClinica has inked a deal with consulting firm Kinapse to help spread the adoption of its risk-based monitoring service, a targeted approach to keeping tabs on trials.
The European Medicines Agency has affirmed its January recommendation, calling for the suspension of more than 700 products tied to improprieties at a GVK Biosciences facility in India.
U.K. CRO Ergomed is expanding its share of the postmarketing services business, buying a medical information firm that fields patient queries for drug companies.
Quintiles, the world's largest CRO, is targeting the growing number of small and midsize biotech companies in Asia, porting its bespoke offering to the region in hopes of partnering with the continent's up-and-coming drug developers.
A group of Quintiles shareholders including the CRO's founder made about $770 million in a secondary stock offering, selling a bulk of shares back to the company and cashing in on its success.
A year removed from taking a private equity buyout, U.K. CRO Quotient Clinical has watched demand for its services spike, the company said, plotting some major investments to keep the pace of growth.
CRO inVentiv Health is amping up its capacity in regulatory compliance to prepare for changes in European trial rules, unveiling a global database it claims can help sponsors avoid costly confusion.
WuXi PharmaTech, China's largest CRO, again boosted its revenue by double digits last quarter, keeping the pace of growth as it considers an offer to go private.
Contract drug developer Patheon has flipped its Mexican operations to Perrigo for $34 million in cash, shifting its focus to the U.S. and Europe.
Evotec, a German company that straddles the line between CRO and biotech, rode its innovative model to revenue growth in the first quarter, raising its expectations for 2015 after signing an expansive deal with Sanofi.
U.S. CRO Theorem Clinical Research is investing in its overseas infrastructure, setting up a new clinical supplies facility in Germany to speed up trials on the continent.
Global CRO QPS Holdings opened a new lab devoted to in vitro research, setting up shop in Fargo, ND, with eyes on early-stage partnerships.
WuXi PharmaTech, China's largest CRO, is considering an offer that would take it private at a sizable premium, forming a committee of independent advisers as it plots its next move.